Confusión respecto a Pembrolizumab (Keytruda), una droga que anuncia un esperado cambio sobre el tratamiento del cáncer.
No Comments
![](https://www.accdis.cl/eng/wp-content/uploads/2018/04/IMAGEN-DESTACADA-11-04-18.jpg)
A landmark cancer drug approved last year seemed to herald a long-anticipated change in the treatment of some tumours: with medicines selected on the basis of molecular markers, rather than the tissue in which the cancer first took root.